Musculoskeletal Solutions was Globus Medical’s largest product and service line in fiscal 2025, bringing in $2.80B of $2.94B (95%).
| Product and Service | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Musculoskeletal Solutions | $926.70M | $1.45B | $2.37B | $2.80B | |||||||||||||
| Spine | — | — | — | — | |||||||||||||
| Innovative Fusion | — | — | — | — | |||||||||||||
| Disruptive Technology | — | — | — | — | |||||||||||||
| Enabling Technologies | $96.14M | $120.22M | $154.00M | $141.01M | |||||||||||||
| Emerging Technology | — | — | — | — | |||||||||||||
| Total | $1.02B | $1.57B | $2.52B | $2.94B |
Globus Medical brought in $2.94B from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 16.7% from $2.52B in fiscal 2024. Musculoskeletal Solutions was the largest at $2.80B (95.2%), ahead of Enabling Technologies at $141.01M (4.8%).
Compared with fiscal 2024, Musculoskeletal Solutions grew 18.3% to $2.80B, while Enabling Technologies fell 8.4% to $141.01M. From fiscal 2022 to 2025, combined revenue from these lines grew from $1.02B to $2.94B, a compound annual growth rate of 42.2%. Musculoskeletal Solutions' share of the total rose from 90.6% to 95.2%.
United States was Globus Medical’s largest region in fiscal 2025, bringing in $2.37B of $2.94B (81%).
| Geography | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $871.94M | $1.28B | $2.00B | $2.37B | |||||||||||||
| International | $150.90M | $288.71M | $519.29M | $571.34M | |||||||||||||
| Total | $1.02B | $1.57B | $2.52B | $2.94B |
Globus Medical brought in $2.94B from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 16.7% from $2.52B in fiscal 2024. United States was the largest at $2.37B (80.6%), ahead of International at $571.34M (19.4%).
Compared with fiscal 2024, United States grew 18.4% to $2.37B and International grew 10.0% to $571.34M. From fiscal 2022 to 2025, combined revenue from these regions grew from $1.02B to $2.94B, a compound annual growth rate of 42.2%. United States' share of the total fell from 85.2% to 80.6%.
Globus Medical (GMED) reports its revenue by product and service and by geography. In fiscal 2025, Musculoskeletal Solutions was its largest product and service line, bringing in $2.80B (95.2% of the total), followed by Enabling Technologies at $141.01M (4.8%).
Musculoskeletal Solutions was Globus Medical's largest product and service line in fiscal 2025, bringing in $2.80B, or 95.2% of the $2.94B total across its two product and service lines.
United States was Globus Medical's largest region in fiscal 2025, bringing in $2.37B, or 80.6% of the $2.94B total across its two regions.
Musculoskeletal Solutions grew faster than Enabling Technologies in fiscal 2025, up 18.3% from $2.37B to $2.80B. Enabling Technologies fell 8.4% to $141.01M.
Every figure comes from Globus Medical's annual financial filings, as reported. Each line keeps the name Globus Medical gives it, and years follow its fiscal calendar.
Globus Medical's revenue by product and service goes back to fiscal 2010, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.